Antioxidant and Antiglycation Properties of Seventeen Fruit Teas Obtained from One Manufacturer

Zieniewska, Izabela; Zalewska, Anna; Żendzian-Piotrowska, Małgorzata; Ładny, Jerzy Robert; Maciejczyk, Mateusz

doi:10.3390/app10155195

Cited by 7 publications

(9 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The glycated/oxidated BSA formation was implemented according to the previously published method [31][32][33][34][35][36]. BSA, of 96% purity, was dissolved in sodium phosphate buffer (1 M, pH 7.4), which contained 0.02% sodium azide as a preservative.…”

Section: Experimental Modelmentioning

confidence: 99%

“…Captopril, Trolox, N-acetylcysteine (NAC), and lipoic acid (ALA) were used as protein oxidation inhibitors, while aminoguanidine and metformin as inhibitors of protein glycation [31][32][33][34][35][36]38]. The concentration of all additives was 1 mM, which was based on the kinetic studies, in proportion to the high concentrations of the glycating agents [31,32,34,35,37,[39][40][41].…”

Section: Oxidative Medicine and Cellular Longevitymentioning

confidence: 99%

See 1 more Smart Citation

Pleiotropic Properties of Valsartan: Do They Result from the Antiglycooxidant Activity? Literature Review and In Vitro Study

Mil

Gryciuk

Pawlukianiec

et al. 2021

Oxidative Medicine and Cellular Longevity

Self Cite

View full text Add to dashboard Cite

Valsartan belongs to angiotensin II type 1 (AT1) receptor blockers (ARB) used in cardiovascular diseases like heart failure and hypertension. Except for its AT1-antagonism, another mechanism of drug action has been suggested in recent research. One of the supposed actions refers to the positive impact on redox balance and reducing protein glycation. Our study is aimed at assessing the antiglycooxidant properties of valsartan in an in vitro model of oxidized bovine serum albumin (BSA). Glucose, fructose, ribose, glyoxal (GO), methylglyoxal (MGO), and chloramine T were used as glycation or oxidation agents. Protein oxidation products (total thiols, protein carbonyls (PC), and advanced oxidation protein products (AOPP)), glycooxidation products (tryptophan, kynurenine, N-formylkynurenine, and dityrosine), glycation products (amyloid-β structure, fructosamine, and advanced glycation end products (AGE)), and albumin antioxidant activity (total antioxidant capacity (TAC), DPPH assay, and ferric reducing antioxidant power (FRAP)) were measured in each sample. In the presence of valsartan, concentrations of protein oxidation and glycation products were significantly lower comparing to control. Moreover, albumin antioxidant activity was significantly higher in those samples. The drug’s action was comparable to renowned antiglycation agents and antioxidants, e.g., aminoguanidine, metformin, Trolox, N-acetylcysteine, or alpha-lipoic acid. The conducted experiment proves that valsartan can ameliorate protein glycation and oxidation in vitro in various conditions. Available animal and clinical studies uphold this statement, but further research is needed to confirm it, as reduction of protein oxidation and glycation may prevent cardiovascular disease development.

show abstract

Section: Experimental Modelmentioning

confidence: 99%

Section: Oxidative Medicine and Cellular Longevitymentioning

confidence: 99%

Pleiotropic Properties of Valsartan: Do They Result from the Antiglycooxidant Activity? Literature Review and In Vitro Study

Mil

Gryciuk

Pawlukianiec

et al. 2021

Oxidative Medicine and Cellular Longevity

Self Cite

View full text Add to dashboard Cite

show abstract

“…The glycated/oxidized BSA formation was performed according to a previously published method [8,9,[27][28][29]59]. Briefly, BSA (purity of 96%) was dissolved in sodium phosphate buffer (0.1 M, pH 7.4) containing 0.02% sodium azide (as a preservative).…”

Section: Bovine Serum Albumin (Bsa)mentioning

confidence: 99%

“…Such experimental conditions are routinely used to determine the anti-glyco-oxidant properties of new substances [8,9,11,12,[25][26][27][28]. To compare the results obtained for meloxicam, aminoguanidine and metformin were used as a known inhibitor of protein glycation, while captopril, Trolox, reduced glutathione and lipoic acid as an antioxidant [8,9,[27][28][29]59]. The concentration of all additives was 1 mM and established on the basis of the other in vitro studies, in proportion to the high concentrations of the glycating agents [8,9,11,12,[25][26][27][28].…”

Section: Bovine Serum Albumin (Bsa)mentioning

confidence: 99%

A New Insight into Meloxicam: Assessment of Antioxidant and Anti-Glycating Activity in In Vitro Studies

et al. 2020

Self Cite

View full text Add to dashboard Cite

Meloxicam is a non-steroidal anti-inflammatory drug, which has a preferential inhibitory effect to cyclooxyganase-2 (COX-2). Although the drug inhibits prostaglandin synthesis, the exact mechanism of meloxicam is still unknown. This is the first study to assess the effect of meloxicam on protein glyco-oxidation as well as antioxidant activity. For this purpose, we used an in vitro model of oxidized bovine serum albumin (BSA). Glucose, fructose, ribose, glyoxal and methylglyoxal were used as glycating agents, while chloramine T was used as an oxidant. We evaluated the antioxidant properties of albumin (2,2-di-phenyl-1-picrylhydrazyl radical scavenging capacity, total antioxidant capacity and ferric reducing antioxidant power), the intensity of protein glycation (Amadori products, advanced glycation end products) and glyco-oxidation (dityrosine, kynurenine, N-formylkynurenine, tryptophan and amyloid-β) as well as the content of protein oxidation products (advanced oxidation protein products, carbonyl groups and thiol groups). We have demonstrated that meloxicam enhances the antioxidant properties of albumin and prevents the protein oxidation and glycation under the influence of various factors such as sugars, aldehydes and oxidants. Importantly, the antioxidant and anti-glycating activity is similar to that of routinely used antioxidants such as captopril, Trolox, reduced glutathione and lipoic acid as well as protein glycation inhibitors (aminoguanidine). Pleiotropic action of meloxicam may increase the effectiveness of anti-inflammatory treatment in diseases with oxidative stress etiology.

show abstract

“…The antioxidant potential of plasma and urine was also assayed using DPPH (1,1-diphenyl-2picrylhydrazyl) radical and Trolox as a standard [23]. The absorbance of DPPH, after decolorization in the presence of antioxidants, was measured spectrophotometrically at 515 nm [31].…”

Section: Radical-scavenging Activity Assay (Dpph)mentioning

confidence: 99%

Plasma and Urine Total Antioxidant Capacity in Patients With Adrenal Tumors

Choromańska

Myśliwiec

Kozłowski

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Total antioxidant capacity better characterizes the redox status of the biological system than the determination of individual antioxidants separately. This study is the first to assess the total antioxidant/oxidant status in the plasma and urine of patients with adrenal tumors. The study group consisted of 60 patients (31 women and 29 men) with adrenal masses, classified into three subgroups: non-functional incidentaloma, pheochromocytoma and Cushing’s/Conn’s adenoma. The number of patients was set a priori based on our previous experiment (α = 0.05, test power = 0.9) Plasma total antioxidant capacity (TAC) was increased in incidentaloma patients, whereas in pheochromocytoma group was decreased. Plasma and urine total oxidant status (TOS) and oxidative stress index (OSI) were significantly higher in patients with adrenal tumors. Ferric reducing antioxidant potential (FRAP) was decreased in plasma and urine, while DPPH (2,2-diphenyl-1-picrylhydrazyl) antiradical activity only in plasma of patients with adrenal masses. In pheochromocytoma patients, plasma and urine TAC, as well as plasma DPPH and FRAP correlated positively with methanephrine and normethanephrine. Reduced levels of TAC, DPPH and FRAP clearly indicate a reduced ability to scavenge free radicals and thus a lack of effective protection against oxidative stress in patients with adrenal tumors. Therefore, those patients are especially vulnerable to oxidative stress and oxidative damage, which can lead to impaired cellular metabolism. Both plasma and urine redox biomarkers can be used to assess systemic antioxidant status in adrenal tumor patients.

show abstract

Antioxidant and Antiglycation Properties of Seventeen Fruit Teas Obtained from One Manufacturer

Cited by 7 publications

References 58 publications

Pleiotropic Properties of Valsartan: Do They Result from the Antiglycooxidant Activity? Literature Review and In Vitro Study

Pleiotropic Properties of Valsartan: Do They Result from the Antiglycooxidant Activity? Literature Review and In Vitro Study

A New Insight into Meloxicam: Assessment of Antioxidant and Anti-Glycating Activity in In Vitro Studies

Plasma and Urine Total Antioxidant Capacity in Patients With Adrenal Tumors

Contact Info

Product

Resources

About